Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $281.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target boosted by Truist Financial from $264.00 to $281.00 in a report issued on Wednesday, Marketbeat reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company boosted their target price on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Needham & Company LLC boosted their price objective on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler lifted their price target on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Finally, Canaccord Genuity Group set a $300.00 price target on Jazz Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $285.44.

Jazz Pharmaceuticals Trading Down 2.6%

Shares of NASDAQ:JAZZ opened at $244.54 on Wednesday. The company has a market capitalization of $15.88 billion, a P/E ratio of 16.86, a P/E/G ratio of 0.23 and a beta of 0.32. Jazz Pharmaceuticals has a 1 year low of $123.88 and a 1 year high of $266.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. The business’s 50 day simple moving average is $247.30 and its 200 day simple moving average is $218.31.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same period last year, the firm earned ($8.25) EPS. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. On average, research analysts anticipate that Jazz Pharmaceuticals will post 21.51 EPS for the current fiscal year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark Douglas Smith sold 1,157 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the transaction, the director directly owned 9,680 shares of the company’s stock, valued at $2,231,724. The trade was a 10.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 14,357 shares of company stock worth $3,505,642 in the last ninety days. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. USA Financial Formulas bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at $25,000. LRI Investments LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter valued at $38,000. Danske Bank A S acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter worth about $40,000. Ameritas Advisory Services LLC bought a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth about $47,000. Finally, Geneos Wealth Management Inc. raised its position in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Higher analyst price targets support the bullish case. Truist raised its JAZZ price target to $281, while Needham and other analysts highlighted the potential for further appreciation. The positive views likely reflect Jazz’s earnings power, specialty-pharmaceutical portfolio and recent revenue growth. Truist Financial Boosts Jazz Pharmaceuticals Price Target
• Positive Sentiment: Jazz is pairing its debt issuance with share repurchases. The company priced an upsized $1.1 billion offering of 1.875% exchangeable senior notes due 2032, up from $1 billion, while announcing concurrent ordinary-share buybacks. The low coupon and repurchases could support capital flexibility and per-share results, although exchangeability creates potential future dilution. Jazz Pharmaceuticals Announces Pricing of Exchangeable Senior Notes
• Positive Sentiment: Roche’s expanded FDA approval for a diagnostic linked to a Jazz cancer medicine may broaden patient identification and market access. The development could help physicians identify appropriate patients for the associated therapy, although the commercial benefit to Jazz depends on adoption and the economics of the diagnostic relationship. Roche Receives Expanded FDA Approval for Diagnostic
• Neutral Sentiment: Jazz’s oncology outlook is being reassessed after Ziihera received first-line approval for HER2-positive gastroesophageal cancer. The approval could increase competition in a key oncology setting, but it also underscores the importance of Jazz’s broader oncology pipeline and product positioning. Ziihera First-Line HER2-Positive GEA Approval
• Negative Sentiment: Zacks Research cut several forward EPS estimates. Its FY2026 forecast fell to $20.77 from $21.72, FY2027 to $20.02 from $22.26, and estimates for multiple quarterly periods were also reduced. Although FY2028 EPS was left broadly stable at $22.74, the near- and medium-term downgrades may pressure sentiment and suggest investors are monitoring growth and execution risks.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.